Recursion Pharmaceuticals, Inc. (RXRX)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Recursion Pharmaceuticals: Unprecedented Scale
Recursion Pharmaceuticals is an AI-enabled drug discovery company, differentiated by its scale and focus on understanding biology. The company has a broad pipeline across various therapeutic areas and strategic partnerships with biopharmaceutical companies. While Recursion is probably the best positioned AI drug discovery company, the stock could pull back if AI hype fades.
Recursion Pharmaceuticals Stock Could Be a 10-Bagger, but Only if It Comes Through on This Big Claim
Recursion hopes to transform the healthcare industry with its innovative drug discovery platform. The small company has gained the interest of Nvidia, which has invested in the business.
1 Disruptive Biotech Stock to Buy Now, and 1 to Consider
Biotechs that aspire to be disruptive are quite risky. However, they do offer the chance of disproportionate rewards.
Is Recursion Pharmaceuticals Stock a Millionaire-Maker?
Recursion Pharmaceuticals hopes to use AI to accelerate drug discovery in the healthcare industry. its ambitious plans are still unproven, and the business has no approved products of its own.
2 Stocks That Could 10x by 2035
Viking Therapeutics is looking to make noise in a fast-growing therapeutic area. Recursion Pharmaceuticals' approach could change the way we develop drugs.
Here is What to Know Beyond Why Recursion Pharmaceuticals, Inc. (RXRX) is a Trending Stock
Recursion Pharmaceuticals (RXRX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
National Bank of Canada FI Buys 1,500 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
National Bank of Canada FI raised its stake in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Free Report) by 90.9% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 3,150 shares of the company’s stock after acquiring an additional 1,500 shares during the period. National Bank of Canada FI’s holdings in Recursion Pharmaceuticals were worth $31,000 as of its most recent SEC filing. Several other hedge funds have also recently bought and sold shares of RXRX. ARK Investment Management LLC grew its holdings in shares of Recursion Pharmaceuticals by 200.4% in the 4th quarter. ARK Investment Management LLC now owns 20,654,287 shares of the company’s stock worth $203,651,000 after purchasing an additional 13,777,689 shares during the last quarter. FMR LLC increased its holdings in shares of Recursion Pharmaceuticals by 134.4% during the third quarter. FMR LLC now owns 10,689,532 shares of the company’s stock worth $81,775,000 after buying an additional 6,129,935 shares in the last quarter. Sumitomo Mitsui Trust Holdings Inc. raised its stake in shares of Recursion Pharmaceuticals by 161.2% in the fourth quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 9,203,780 shares of the company’s stock valued at $90,749,000 after acquiring an additional 5,680,656 shares during the last quarter. Vanguard Group Inc. boosted its holdings in shares of Recursion Pharmaceuticals by 37.7% in the 3rd quarter. Vanguard Group Inc. now owns 15,506,834 shares of the company’s stock worth $118,627,000 after acquiring an additional 4,247,002 shares in the last quarter. Finally, Rafferty Asset Management LLC grew its position in Recursion Pharmaceuticals by 244.7% during the 3rd quarter. Rafferty Asset Management LLC now owns 1,104,526 shares of the company’s stock worth $8,450,000 after acquiring an additional 784,113 shares during the last quarter. 89.06% of the stock is currently owned by institutional investors and hedge funds. Insider Buying and Selling at Recursion Pharmaceuticals In other news, Director Blake Borgeson sold 20,054 shares of the firm’s stock in a transaction on Tuesday, February 20th. The stock was sold at an average price of $12.32, for a total value of $247,065.28. Following the transaction, the director now directly owns 7,292,863 shares in the company, valued at approximately $89,848,072.16. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, Director Blake Borgeson sold 20,054 shares of the business’s stock in a transaction that occurred on Tuesday, February 20th. The shares were sold at an average price of $12.32, for a total transaction of $247,065.28. Following the completion of the transaction, the director now owns 7,292,863 shares in the company, valued at $89,848,072.16. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, COO Tina Marriott sold 8,000 shares of the stock in a transaction on Thursday, February 22nd. The stock was sold at an average price of $14.89, for a total transaction of $119,120.00. Following the completion of the sale, the chief operating officer now owns 639,982 shares in the company, valued at $9,529,331.98. The disclosure for this sale can be found here. In the last 90 days, insiders sold 327,946 shares of company stock worth $3,238,953. Insiders own 15.75% of the company’s stock. Recursion Pharmaceuticals Stock Down 0.9 % Recursion Pharmaceuticals stock opened at $9.42 on Monday. The stock has a market cap of $2.21 billion, a price-to-earnings ratio of -5.89 and a beta of 0.85. Recursion Pharmaceuticals, Inc. has a 12-month low of $4.97 and a 12-month high of $16.75. The business’s 50-day simple moving average is $9.17 and its 200 day simple moving average is $9.47. Recursion Pharmaceuticals (NASDAQ:RXRX – Get Free Report) last issued its quarterly earnings results on Thursday, May 9th. The company reported ($0.39) EPS for the quarter, topping the consensus estimate of ($0.43) by $0.04. Recursion Pharmaceuticals had a negative net margin of 765.90% and a negative return on equity of 79.96%. The company had revenue of $13.80 million during the quarter, compared to analysts’ expectations of $11.10 million. During the same quarter in the previous year, the company earned ($0.34) EPS. Recursion Pharmaceuticals’s revenue was up 14.0% on a year-over-year basis. As a group, sell-side analysts expect that Recursion Pharmaceuticals, Inc. will post -1.6 EPS for the current year. Analysts Set New Price Targets A number of equities analysts have commented on RXRX shares. Needham & Company LLC reissued a “buy” rating and issued a $17.00 price objective on shares of Recursion Pharmaceuticals in a research note on Friday, May 10th. KeyCorp raised their price objective on shares of Recursion Pharmaceuticals from $15.00 to $16.00 and gave the company an “overweight” rating in a research report on Monday, March 4th. Finally, TD Cowen started coverage on shares of Recursion Pharmaceuticals in a research note on Friday, January 26th. They set a “market perform” rating on the stock. Three investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Recursion Pharmaceuticals currently has a consensus rating of “Hold” and an average price target of $12.75. Check Out Our Latest Stock Analysis on Recursion Pharmaceuticals Recursion Pharmaceuticals Profile (Free Report) Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Read More Five stocks we like better than Recursion Pharmaceuticals What Are Dividend Contenders? Investing in Dividend Contenders MarketBeat Week in Review – 5/13 – 5/17 Manufacturing Stocks Investing Take-Two Interactive Software Offers 2nd Chance for Investors Are Penny Stocks a Good Fit for Your Portfolio? Deere & Company’s Q2 Report: Strong Revenue, Cautious Outlook Want to see what other hedge funds are holding RXRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Free Report).
